Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.
All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.
Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.
Purpose-built solutions. Proven results. User & Patient-centered innovation.
Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity. Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.
We are the Innovation CRO.
Legacy of excellence. Proven execution. Patient impact accelerated.
225,000 vitrectomy surgeries are performed annually in the U.S. A time-driven cost analysis conducted at a US academic hospital found the average true cost of routine vitrectomies (including macular hole (MH) surgeries) is $7,169.79 per patient, $2,000 above CMS’s 2019 reimbursed rate. This analysis aims to quantify the potential cost impact of improved MH closure rates using a 3D-HUD system at a US academic hospital.
